Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Laetitia Fend(Transgene (France)), Takahiro Yamazaki(Université Paris-Sud), Christelle Remy(Transgene (France)), Catherine Fahrner(Transgene (France)), Murielle Gantzer(Transgene (France)), Virginie Nourtier(Transgene (France)), Xavier Préville(Transgene (France)), Éric Quéméneur(Transgene (France)), Oliver Kepp(Délégation Paris 5), Julien Adam(Institut Gustave Roussy), Aurélien Marabelle(Inserm), Jonathan M. Pitt(Université Paris-Sud), Guido Kroemer(Délégation Paris 5), Laurence Zitvogel(Université Paris-Sud)
Cancer Research
May 23, 2017
Cited by 125

Abstract

Abstract Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatment, the ability to induce immune-mediated regression of distant metastases is still poorly documented. We report here that the engineered oncolytic vaccinia virus VVWR-TK−RR−-Fcu1 can induce immunogenic cell death and generate a systemic immune response. Effects on tumor growth and survival was largely driven by CD8+ T cells, and immune cell infiltrate in the tumor could be reprogrammed toward a higher ratio of effector T cells to regulatory CD4+ T cells. The key role of type 1 IFN pathway in oncolytic virotherapy was also highlighted, as we observed a strong abscopal response in Ifnar−/− tumors. In this model, single administration of virus directly into the tumors on one flank led to regression in the contralateral flank. Moreover, these effects were further enhanced when oncolytic treatment was combined with immunogenic chemotherapy or with immune checkpoint blockade. Taken together, our results suggest how to safely improve the efficacy of local oncolytic virotherapy in patients whose tumors are characterized by dysregulated IFNα signaling. Cancer Res; 77(15); 4146–57. ©2017 AACR.


Related Papers

No related papers found

Powered by citation graph analysis